Recursion has announced a regulatory milestone for REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), as it prepares to begin a registrational Phase 3 trial ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
The "Subject B" exam, which consists of 20 questions to be solved in 100 minutes, significantly impacts whether you pass or ...
点击上方“Deephub Imba”,关注公众号,好文章不错过 !数据分块可以把超大文档拆成 AI ...
A Beginner's Guide to the Sliding Window Algorithm with JavaScript Learn the basics of the Sliding Window algorithm in ...
The new closed-loop discovery system outperformed AI systems from OpenAI and Anthropic on a public biology benchmark, advancing scientific discovery through autonomous experimentation at scale. NEW ...
Candidates preparing for the GATE 2027 Data Science and Artificial Intelligence (DA) paper can use the previous three ...
Box ManipulationIn the history of artificial intelligence and machine learning, the determination of internal parameters ...
System logs generated by globally distributed microservices often hide subtle degradations (like memory thrashing or systemic ...
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
Anthropic claims to be near something along the lines of recursive self-improvement, or RSI, according to the latest revision of its S-1/A filing, published Monday. The new warning in the “Risk ...